Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Verma

Showing results (541-550 of 562) with videos related to

Pageof 57
Sort By:
Cancer Treatment and Research Communications|January 20, 2022
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung CancerSteven H Lin, Heather Y Lin, Vivek Verma, et al.
JAMA Oncology|September 19, 2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal CancerDawei Chen, Hari Menon, Vivek Verma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
The Lancet. Respiratory Medicine|October 23, 2020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsWillemijn S M E Theelen, Dawei Chen, Vivek Verma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Performance Status Restriction in Phase III Cancer Clinical TrialsJoseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, et al.
Leukemia & Lymphoma|January 22, 2021
The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapyAlexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, et al.
Cancer|October 15, 2016
Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumorsVivek Verma, Valerie K Shostrom, Sameera S Kumar, et al.
Nature Immunology|July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Nature Immunology|September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 57

Showing results (541-550 of 562) with videos related to

Sort By:
Pageof 57
Cancer Treatment and Research Communications|January 20, 2022
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung CancerSteven H Lin, Heather Y Lin, Vivek Verma, et al.
JAMA Oncology|September 19, 2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal CancerDawei Chen, Hari Menon, Vivek Verma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
The Lancet. Respiratory Medicine|October 23, 2020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsWillemijn S M E Theelen, Dawei Chen, Vivek Verma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Performance Status Restriction in Phase III Cancer Clinical TrialsJoseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, et al.
Leukemia & Lymphoma|January 22, 2021
The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapyAlexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, et al.
Cancer|October 15, 2016
Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumorsVivek Verma, Valerie K Shostrom, Sameera S Kumar, et al.
Nature Immunology|July 31, 2019
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Nature Immunology|September 26, 2019
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistanceVivek Verma, Rajeev K Shrimali, Shamim Ahmad, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 57